FDA granted accelerated approval to an oncolytic viral therapy for anti-PD-1-refractory melanoma — Tudriqev plus nivolumab, on a 91-patient single-arm response rate (FDA, 6 Aug 2026)

Why it matters (spine). A genetically modified virus injected directly into a tumour is now an approved therapy for patients whose melanoma has stopped responding to checkpoint blockade — a population with few options. The FDA's own notice states the indication precisely: "On August 6, 2026, the Food and Drug Administration granted accelerated approval to vusolimogene oderparepvec-wtpg (Tudriqev, Replimune, Inc.), a genetically modified oncolytic viral therapy, in combination with nivolumab for the treatment of adult patients with unresectable advanced cutaneous melanoma who experienced disease progression on a programmed death receptor-1 (PD-1)-blocking antibody-based regimen." The money angle is a commercially approved product in a refractory oncology indication built on an engineered-biology platform rather than a small molecule. The metacrisis lever is narrow and honest: this is treatment of established disease, not prevention, and nothing here touches the non-toxic-exposure spine.

The evidence, and its shape. IGNYTE (NCT03767348) is described by the FDA as "an open-label, multiregional, single-arm trial in 140 adult patients with Stage IIIB, IIIC or IV unresectable advanced melanoma who experienced disease progression on at least eight consecutive weeks of prior anti-PD-1-based therapy." Of those 140, "91 patients with at least one noninjected lesion were included in the efficacy-evaluable population." The major efficacy outcome measures were objective response rate and duration of response: "ORR was 24.2% (15.8, 34.3) and the median DOR was 14.1 months (10.7, not reached)." Two things follow that the headline will not carry. There is no control arm, so no comparison against continued standard care exists in this dataset. And the FDA notice reports the interval (15.8, 34.3) without labelling it — this card reproduces it as printed and does not assert it is a 95% confidence interval.

Accelerated is not confirmed, and the notice says so. "The approval was granted under the FDA's accelerated approval pathway based on objective response rate and duration of response. As a condition of accelerated approval, Replimune, Inc., is required to conduct post-approval trial(s) to verify and describe the clinical benefit of Tudriqev in combination with nivolumab. Continued approval may be contingent upon verification of clinical benefit in confirmatory trial(s)." Response rate is a surrogate. Neither overall survival nor progression-free survival appears anywhere in this notice.

Safety and administration, as printed. The FDA notice reports that "The prescribing information includes warnings and precautions for accidental exposure, herpetic infection or reactivation, injection procedure complications, and immune-mediated events." That is the notice's summary of the label; the label itself was not opened for this card. Dosing is intratumoral: "1 mL/cm of the largest dimension of the tumor, for a maximum of 10 mL across all lesions treated per dose," given "every two weeks for eight consecutive doses, beginning at a concentration of 10⁶ plaque-forming units (PFU) per mL at Week 1, followed by 10⁷ PFU per mL for subsequent doses," with nivolumab administered intravenously from Week 3. The combination held breakthrough therapy designation.

What would prove it wrong (falsifier). The regulatory fact fails if the FDA notice is withdrawn or corrected, or if Drugs@FDA does not post prescribing information for Tudriqev. The clinical claim — that this helps patients live longer or better — has a sharper falsifier already built into the approval: if the required confirmatory trial(s) fail to verify clinical benefit, continued approval may be withdrawn, which is the explicit condition the FDA attached. A 24.2% response rate in a single arm is also consistent with a therapy that helps a minority substantially and most patients not at all; nothing in this notice distinguishes those cases.

What this card deliberately does not carry. The FDA states that "On July 30, 2026, the FDA convened the Cellular, Tissue, and Gene Therapies Advisory Committee Meeting to discuss this application" — which settles that the meeting the 30 July card described in the future tense actually happened. The committee's vote tally does not appear on this card. A vote count circulated during the sweep, but its only sources were trade coverage and a scout-relayed snippet; the FDA notice does not state a tally, and a lead is not a fact. No pricing, no launch date, and no market-size figure appears here, because none appears in the primary. The viral platform is likewise not named: the notice says only "a genetically modified oncolytic viral therapy," so this card says no more, and the "herpetic infection or reactivation" warning is reproduced as a warning rather than read as a platform disclosure.

Relation to the existing card, and its own promotion rule. This supersedes nothing and resolves one thing. replimune-rp1-ctgt-advisory-committee (dated 30 July 2026, held at signal precisely because its Form 8-K documented a scheduled meeting in the future tense) set a re-verification trigger for the next sweep. That trigger has fired. It is worth being explicit that the earlier card also wrote its own promotion route — "It is promoted to verified — with the outcome attached — from … an approval letter or complete-response letter appearing in the agency's own record" — and that route has now been met. The promotion is being declined deliberately, not overlooked: the outcome is carried here, on its own primary and its own date, and the earlier card is left at signal as written, because corrections are logged rather than erased and its signal tier was correct for the document it cited.

Provenance (what I actually read). Fetched the FDA's approval notice at fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma from the main thread on 21 August 2026. The page carries article:published_time of Thu, 08/06/2026 - 15:54 and states "Content current as of: 08/06/2026"; the creator is recorded as the Center for Drug Evaluation and Research. Figures and quotations taken directly from that notice: the approval date 6 August 2026 and the full indication sentence; the trial identifier NCT03767348 and the trial-design sentence, including the Stage IIIB/IIIC/IV eligibility language and the eight-week prior-therapy threshold; 140 enrolled and 91 efficacy-evaluable; ORR 24.2% with the interval (15.8, 34.3); median DOR 14.1 months with the interval (10.7, not reached); the accelerated-approval-pathway and confirmatory-trial condition sentences; the 30 July advisory-committee sentence; the warnings-and-precautions sentence; the dosing volumes, schedule and PFU concentrations; and the breakthrough therapy designation. Every other number circulating about this approval was excluded. I did not open the prescribing information itself, the FDA briefing document, or Replimune's own release, so nothing sourced to those appears above — the label content above is the notice's own summary of the label, quoted as such.